BioPharmSignal logoBioPharmSignal

Biotech News

Chemomab Therapeutics Announces Year End and Fourth Quarter 2025 Financial Results and Provides a Corporate Update

Chemomab Therapeutics (CMMB)Chemomab TherapeuticsEarnings

CMMB (CMMB) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is cmmb.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Open original release

Related news

CMMBChemomab Therapeutics2026-05-14 12:00 EST

Chemomab Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update

NRIXNurix Therapeutics2026-04-08 10:00 EST

Nurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

IMVTImmunovant2026-05-20 11:00 EST

Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026

AVTXAvalo Therapeutics2026-05-13 11:00 EST

Avalo Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates

GPCRStructure Therapeutics2026-05-07 20:06 EST

Structure Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights

KYMRKymera2026-04-30 11:00 EST

Kymera Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update

BNTXBioNTech2026-07-21 10:45 EST

BioNTech to Report Second Quarter 2026 Financial Results and Corporate Update on August 4, 2026

CLDXCelldex Therapeutics2026-05-07 20:01 EST

Celldex Reports First Quarter Financial Results and Provides Corporate Update

ZURAZura Bio2026-05-07 11:30 EST

Zura Bio Reports First Quarter 2026 Financial Results and Recent Corporate Updates

BNTXBioNTech2026-05-05 10:45 EST

BioNTech Announces First Quarter 2026 Financial Results and Corporate Update

View all latest news

Chemomab Therapeutics

Chemomab Therapeutics is a biotechnology company focused on fibrosis and inflammatory disease biology. Its story is centered on targeting tough chronic conditions where disease-modifying therapies are still needed.

Recent company news

CMMBChemomab Therapeutics2026-07-08 11:30 EST

Chemomab Therapeutics and Precision Medicine Pioneer Scipher Medicine Announce Merger Agreement to Advance Nebokitug in an AI-Powered Phase 2 Trial in Rheumatoid Arthritis

CMMBChemomab Therapeutics2026-05-14 12:00 EST

Chemomab Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update

CMMBChemomab Therapeutics2026-03-19 12:00 EST

Chemomab Therapeutics Announces Year End and Fourth Quarter 2025 Financial Results and Provides a Corporate Update

CMMBChemomab Therapeutics2026-02-17 13:00 EST

Chemomab Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference

CMMBChemomab Therapeutics2025-12-02 13:00 EST

Chemomab Therapeutics Announces Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis Published in the American Journal of Gastroenterology

Stock data

Close
1.42 USD
Market cap
12.53M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States